CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.
Zöphel S, Küchler N, Jansky J, Hoxha C, Schäfer G, Weise JJ, Vialle J, Kaschek L, Stopper G, Eichler H, Yildiz D, Moter A, Wendel P, Ullrich E, Schormann C, Rixecker T, Cetin O, Neumann F, Orth P, Bewarder M, Hoth M, Thurner L, Schwarz EC.
Zöphel S, et al. Among authors: yildiz d.
Mol Cancer. 2024 Sep 28;23(1):210. doi: 10.1186/s12943-024-02123-7.
Mol Cancer. 2024.
PMID: 39342291
Free PMC article.